



# Crystal structure of bacterial cytotoxic necrotizing factor CNF<sub>γ</sub> reveals molecular building blocks for intoxication

Paweena Chaoprasid<sup>1,2,†</sup> , Peer Lukat<sup>3,†</sup> , Sabrina Mühlen<sup>1,2,4,†</sup> , Thomas Heidler<sup>5</sup> , Emerich-Mihai Gazdag<sup>3</sup> , Shuangshuang Dong<sup>3</sup> , Wenjie Bi<sup>6</sup> , Christian Rüter<sup>1</sup> , Marco Kirchenwitz<sup>7</sup> , Anika Steffen<sup>7</sup> , Lothar Jänsch<sup>6,8</sup> , Theresia E B Stradal<sup>7,8</sup> , Petra Dersch<sup>1,2,4,9,\*</sup> & Wulf Blankenfeldt<sup>3,10,\*\*</sup>

## Abstract

Cytotoxic necrotizing factors (CNFs) are bacterial single-chain exotoxins that modulate cytokinetic/oncogenic and inflammatory processes through activation of host cell Rho GTPases. To achieve this, they are secreted, bind surface receptors to induce endocytosis and translocate a catalytic unit into the cytosol to intoxicate host cells. A three-dimensional structure that provides insight into the underlying mechanisms is still lacking. Here, we determined the crystal structure of full-length *Yersinia pseudotuberculosis* CNF<sub>γ</sub>. CNF<sub>γ</sub> consists of five domains (D1–D5), and by integrating structural and functional data, we demonstrate that D1–3 act as export and translocation module for the catalytic unit (D4–5) and for a fused β-lactamase reporter protein. We further found that D4, which possesses structural similarity to ADP-ribosyl transferases, but had no equivalent catalytic activity, changed its position to interact extensively with D5 in the crystal structure of the free D4–5 fragment. This liberates D5 from a semi-blocked conformation in full-length CNF<sub>γ</sub>, leading to higher deamidation activity. Finally, we identify CNF translocation modules in several uncharacterized fusion proteins, which suggests their usability as a broad-specificity protein delivery tool.

**Keywords** AB-toxin; ADP-ribosyl transferase; CNF; DUF4765; *Yersinia*

**Subject Categories** Microbiology, Virology & Host Pathogen Interaction; Structural Biology

DOI 10.15252/embj.2020105202 | Received 6 April 2020 | Revised 12 November 2020 | Accepted 23 November 2020 | Published online 7 January 2021

The EMBO Journal (2021) 40: e105202

## Introduction

Among the plethora of traits developed by pathogenic bacteria to establish infections, toxins play the most prominent role, since they are responsible for the majority of clinical symptoms (Popoff, 2005). Many bacterial exotoxins are key virulence factors that target different functions of host cells to break barriers, improve access to nutrients, defeat immune responses, and promote bacterial dissemination within and among hosts.

The cytotoxic necrotizing factors (CNFs) belong to a class of bacterial exotoxins that deamidate a glutamine (Q61 or Q63) in the active site (switch-II region) of host cell proteins belonging to the small Rho GTPase family, i.e. RhoA, Rac1, and Cdc42 (Flatau *et al*, 1997; Schmidt *et al*, 1997; Knust & Schmidt, 2010). This locks these key regulators in their active state, causing a multitude of downstream effects that are most readily observed as alterations of the actin cytoskeleton or perturbations of other cellular processes including phagocytosis, cell proliferation (multinucleation), reactive oxygen species production, and the release of anti-apoptotic and pro-inflammatory factors (Fabbri *et al*, 2013; Hodge & Ridley, 2016; Ho *et al*, 2018). The consequences of these effects are changes of innate immune responses and tissue damage, leading to the

1 Institute of Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Münster, Germany

2 Molecular Infection Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany

3 Structure and Function of Proteins, Helmholtz Centre for Infection Research, Braunschweig, Germany

4 Deutsches Zentrum für Infektionsforschung, Braunschweig, Germany

5 Molecular Structural Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany

6 Cellular Proteomics, Helmholtz Centre for Infection Research, Braunschweig, Germany

7 Cell Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany

8 Institute of Zoology, Technische Universität Braunschweig, Braunschweig, Germany

9 Institute of Microbiology, Technische Universität Braunschweig, Braunschweig, Germany

10 Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braunschweig, Braunschweig, Germany

\*Corresponding author. Tel: +49 251 83 56466; E-mail: petra.dersch@uni-muenster.de

\*\*Corresponding author. Tel: +49 531 6181 7000; E-mail: wulf.blankenfeldt@helmholtz-hzi.de

†These authors contributed equally to this work

development of acute disease symptoms (Knust & Schmidt, 2010; Schweer et al, 2013; Diabate et al, 2015; Cavaillon, 2018; Heine et al, 2018).

CNFs are found in several pathogenic bacteria, predominantly in pathogenic *Escherichia coli*, but also in *Yersinia pseudotuberculosis*, *Shigella* species, *Salmonella enterica*, as well as in *Moritella viscosa* and *Photobacterium damsela*, pathogens of economically important fish (Fig EV1; Morgan et al, 2019). In addition, CNFs show local homology to other toxins such as the dermonecrotizing toxin DNT of *Bordetella pertussis* and the PMT toxin of *Pasteurella multocida* (Walker & Weiss, 1994), indicating that these proteins consist of common structural building blocks that have been interchanged in the course of evolution.

CNF1, the most thoroughly investigated representative of the CNF family, is a major virulence factor in uropathogenic *E. coli* (UPEC) strains, which live in the intestine and enter the urinary tract via the urethra (Boquet, 2001; Knust & Schmidt, 2010; Ho et al, 2018). CNF1-containing strains exhibit a higher viability, have a higher potential to colonize the urinary tract, affect the function of immune cells and increase the inflammation rate (Falzano et al, 1993; Fournout et al, 2000; Rippere-Lampe et al, 2001). CNF1 was also identified in some intestinal and extraintestinal *E. coli* (ExPEC) where it was found to increase bacterial invasion into endothelial cells (Khan et al, 2002) and to promote malignant tumor conversion and intestinal cell invasiveness (Zhang et al, 2018; Fabbri et al, 2019). Similarly, the homologous toxin CNF<sub>Y</sub>, which shares 65% identity with *E. coli* CNF1, is crucial for the pathogenicity of *Y. pseudotuberculosis*, which causes food-borne and zoonotic enteric infections that manifest themselves as enteritis, mesenteric lymphadenitis and more rarely, in sequelae such as reactive arthritis (Smego et al, 1999; Koornhof et al, 1999; Heine et al, 2018). The importance of CNF<sub>Y</sub> is emphasized by the fact that a knock-out mutation of the *cnfY* gene leads to avirulence, allowing bacteria to become persistent in mice (Heine et al, 2018). Recent studies demonstrated that Rho GTPase activation by CNF<sub>Y</sub> enhances the translocation of *Yersinia* outer proteins (Yops) into neutrophils and macrophages via a type III secretion system (T3SS). This blocks phagocytosis, triggers immune cell death, and contributes to massive tissue damage by induction of pro-inflammatory responses and necrosis (Schweer et al, 2013; Wolters et al, 2013).

CNFs may also hold promise for treatment of neurological disorders and cancer (Maroccia et al, 2018). For example, CNF1 injection into brains of mice enhanced neurotransmission and synaptic plasticity, leading to improved learning and memory (Diana et al, 2007). Moreover, CNF1 was able to rescue wildtype-like mitochondrial morphology in fibroblasts derived from patients with myoclonic epilepsy, and it reduced tumor growth (Vannini et al, 2016; Fabbri et al, 2018). As CNFs efficiently intoxicate a broad range of host cells, transport modules of the toxin may also be useful for drug delivery (Haywood et al, 2018). To exploit and further develop this tool, detailed knowledge of the molecular mechanisms underlying CNF secretion, translocation, and activity is required. However, little is known about the global structure and the individual functional units of CNFs and so far, only the structure of the catalytic domain of CNF1 has been determined (Buetow et al, 2002).

At the sequence level, CNF-type toxins of different species share at least 55% overall identity (Fig EV1), indicating similar structures and conserved modes-of-action, although they show

differential preferences with respect to the targeted Rho GTPase and interact with different host cell receptors (Hoffmann et al, 2004; Blumenthal et al, 2007). CNF1 uses two cellular receptors to enter host cells via endocytosis, the 37-kDa laminin receptor precursor p37LRP, which is recognized by sequences located within the N-terminus of the toxin, and the Lutheran adhesion glycoprotein/basal cell adhesion molecule (Lu/BCAM), which interacts with motifs in the C-terminal half (Fabbri et al, 1999; Chung et al, 2003; Kim et al, 2005; McNichol et al, 2007; Piteau et al, 2014; Reppin et al, 2017). The receptor of the N-terminal part of CNF<sub>Y</sub> is still unknown, but it has been shown that binding of CNF1 to host cells has no effect on CNF<sub>Y</sub> uptake (Blumenthal et al, 2007), suggesting that both toxins use different host cell factors for endocytosis. This has also been corroborated in a recent study that identified glycosaminoglycans as interaction partners of C-terminal fragments of CNF<sub>Y</sub> (preprint: Kowarschik et al, 2020). The CNFs are taken up into endosomes and their release into the host cytoplasm requires two hydrophobic sequence motifs within the N-terminal half of the toxin that have been predicted to form  $\alpha$ -helices. These helices are separated by a loop containing an acidic patch of four conserved acidic amino acids, and they are believed to insert into the endosomal membrane upon charge neutralization of the patch in the course of endosome acidification (Pei et al, 2001). An unidentified protease then cleaves CNF (i.e., CNF1 between residues 532 and 544), and the C-terminal fragment including the catalytic domain (residues 720–1,014) is released into the cytosol of the host cell to mediate the cellular effects of the toxin (Pei et al, 2001; Knust et al, 2009).

In this study, we resolved the crystal structure of the full-length *Y. pseudotuberculosis* CNF<sub>Y</sub> protein, necessary to achieve an understanding of its transport and functional mechanisms and its potential therapeutic use. The CNF<sub>Y</sub> structure revealed a complex set-up of five individual building blocks and allowed us to obtain detailed information about the minimal secretion and translocation domain required to transport the catalytic domain or a fused cargo protein into the host cell cytosol, which could be exploited for drug delivery.

## Results

### CNF<sub>Y</sub> contains five structural building blocks

Recombinant full-length CNF<sub>Y</sub> was produced in *E. coli* (Appendix Fig S1) and crystallized in space group I2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>. These crystals diffracted to 2.7 Å and contained one CNF<sub>Y</sub> molecule in the asymmetric unit. Since no suitable search model for molecular replacement was available and crystallization of full-length seleno-L-methionine-labeled protein failed, we also crystallized different fragments of CNF<sub>Y</sub>: (i) one containing only the deamidase domain (residues 720–1,014), (ii) another consisting of the subunit which is likely released into the cytosol (residues 526–1,014) based on the homology to *E. coli* CNF1 (Hoffmann et al, 2004; Blumenthal et al, 2007), and (iii) a third fragment including the complete N-terminal portion with parts of the released subunit (residues 1–704) (Appendix Fig S1). A detailed description of structure determination by Se-SAD and molecular replacement is given in the Materials and Methods section and an overview over data collection and

refinement statistics as well as the respective Protein Data Bank (Berman *et al*, 2000) deposition codes is provided in Table EV1.

CNF<sub>Y</sub> adopts a compact, modular structure of five structural building blocks (D1–D5) with approximate dimensions of 115\*73\*65 Å (Fig 1A–C). All residues of the protein could be traced in the structure of the holo-protein with the exception of residues N430-K431, S550-L553, and P701-L717. The unresolved amino acids resided in surface loops, indicating intrinsic flexibility. Analysis with PiSQRD (Aleksiev *et al*, 2009) assigns domain boundaries to residues 1–22/135–424 (D1), 23–134 (D2), 425–529 (D3), 530–700 (D4), and 718–1,014 (D5, deamidase domain). The compact arrangement of D1–D5 in the full-length structure of CNF<sub>Y</sub> prompted us to investigate the interactions between the five individual domains of CNF<sub>Y</sub> in more detail. Analysis with PISA (Krissinel & Henrick, 2007) reveals large hydrophobic interfaces between D1 and D2 (interface area 870 Å<sup>2</sup>) as well as between D3 and D4 (750 Å<sup>2</sup>) (Appendix Table S1). The C-terminal domain D5 interacts mainly with D3 (610 Å<sup>2</sup>), which, as a consequence, partially blocks the entrance to the catalytic site. D5 interacts only weakly with D4 (380 Å<sup>2</sup>), which itself establishes an extensive interface with D1 (1,390 Å<sup>2</sup>) (Fig 1C).

The crystal structure of the fragment comprising residues 1–704 (D1–D4) is fully superimposable with the respective residues of the holo-protein. The isolated D4–D5 fragment, on the other hand, showed a different orientation of the two domains with respect to the full-length protein and was thus included into the following more detailed structure–function analysis together with full-length CNF<sub>Y</sub>.

### Structural analysis and structure-guided mutagenesis provide insight into the function of the structural building blocks of CNF<sub>Y</sub>

In order to gain insights into the biological function of the individual building blocks, we performed a detailed structural analysis of the full-length CNF<sub>Y</sub> (D1–D5) and constructed truncated, mutated, and marker-tagged versions of CNF<sub>Y</sub> to investigate their secretion, translocation, and enzymatic activity in human epithelial cells. The truncations were designed to interrupt the protein within linker regions between the individual domains (Fig 2A). CNF<sub>Y</sub> variants were produced in *Y. pseudotuberculosis* or as recombinant proteins from *E. coli* (Fig 2B, Appendix Fig S1). Their enzymatic activity was tested with bacterial extracts or purified proteins by assessing their ability to deamidate RhoA in intact HEP-2 cells and host cell extracts, and by assessing the induction of actin rearrangements and the inhibition of cell division (formation of multinuclear cells) (Fig 3). The ability to bind to host cells was tested with 3xFlag-tagged versions of the CNF<sub>Y</sub> derivatives (Fig 2D), and their capacity to reach late endosomes was measured with CNF<sub>Y</sub>-GFP fusion variants (Fig 4). CNF<sub>Y</sub> export from the bacterial cell and cytosolic translocation of the CNF<sub>Y</sub> activity domain were detected with CNF<sub>Y</sub>-β-lactamase (TEM) constructs (Figs 2C and 3A). Secretion of the CNF<sub>Y</sub>-TEM derivatives was analyzed by incubation of bacterial culture supernatants with nitrocefin, a chromogenic cephalosporin substrate used to detect β-lactamases. Translocation of the CNF<sub>Y</sub>-TEM fusion proteins was detected by staining the cytosol of host cells with the FRET substrate CCF4-AM, which contains the coumarin- and fluorescein-conjugated β-lactam cephalosporin and is green fluorescent (excitation at 409 nm, emission at 530 nm).

Cleavage of the β-lactam ring shifts the fluorescence of the compound to blue (emission at 450 nm) and thus indicates the presence of TEM β-lactamase in the cytosol.

For validation, we first tested marker-tagged full-length wildtype CNF<sub>Y</sub> (CNF<sub>Y</sub> 1–1,014) and a mutant derivative, namely CNF<sub>Y</sub> C866S. This substitution inactivated the deamidase activity when introduced into *E. coli* CNF1 (Hoffmann *et al*, 2004). The marker-tagged versions of the full-length CNF<sub>Y</sub> wildtype protein were efficiently produced (Fig 2B), secreted (Fig 2C), and internalized into host cells (Fig 2D). Inside cells they were targeted to the late endosome (Fig 4) and translocated into the host cell cytosol (Fig 3A) to deamidate RhoA (Fig 3B) and induce formation of stress fibers or polynucleation in cultured cells (Fig 3C). In contrast, all CNF<sub>Y</sub> C866S derivatives were found to abrogate the RhoA deamidation and induction of multinucleated cells, whereas other properties were not affected (Figs 2B–D and 3). Together, this demonstrates the suitability of the employed test systems.

### Domain D1 is a major component of the translocation apparatus in CNFs

The crystal structure of CNF<sub>Y</sub> revealed that domain D1 consists of separate areas covering residues 1–22 and 135–424, which together form a bundle of α-helices flanked by a four-stranded anti-parallel β-sheet that is covered with three α-helices from the other side (Figs 1B and EV2). Sequences within domain D1 have previously been shown to contain elements that are required for translocation of the catalytic fragment of *E. coli* CNF1 (Pei *et al*, 2001; Knust *et al*, 2009), suggesting that this domain is a major component of the translocation machinery of CNFs.

Although domain D1 of CNF<sub>Y</sub> is, due to its overall α-helical character, reminiscent of the translocation domain of other toxins such as diphtheria toxin (DT), searches with DALI (Holm & Rosenström, 2010) detected no significant structural homology to these proteins. Instead, it identified only the segment containing the four-stranded anti-parallel β-sheet (residues 152–343) as being somewhat similar to a fragment of the translocation domain of nigratoxin, a toxin of crustaceans and insects (PDB entry 5M41; 177 residues aligned, rmsd 3.8 Å, 11% sequence identity) (Fig 5A) (Labreuche *et al*, 2017). However, the translocation domain of nigratoxin is significantly smaller than the D1 domain of CNF<sub>Y</sub> and does not contain hydrophobic sequence motifs that have previously been predicted to be essential for translocation in CNFs and other toxins (Pei *et al*, 2001; Orrell *et al*, 2017), hinting at distinct translocation mechanisms.

To gain further insight into the function of D1, we constructed marker-tagged CNF<sub>Y</sub> derivatives containing different deletions within the domain (Δ39–134, Δ134–426, Δ39–426; Fig 2A). The CNF<sub>Y</sub> Δ134–426 derivative was less efficiently produced and inactive (i.e., it did not deamidate RhoA in host cell extracts, Figs 2B and 3B), indicating that it is improperly folded and less stable. However, the CNF<sub>Y</sub> Δ39–134 and CNF<sub>Y</sub> Δ39–426 proteins were well expressed (Fig 2B) and enzymatically active (Figs 2C and 3B), yet, they failed to be secreted (Fig 2C) or translocated as indicated by their inability to trigger RhoA activation when added to host cells (Fig 3B). On the other hand, a C-terminally truncated CNF<sub>Y</sub> protein containing the entire domain D1 (1–443) was secreted efficiently (Fig 2C), corroborating that this segment is necessary and sufficient for CNF<sub>Y</sub> to exit the bacterial cell.




Figure 1.

**Figure 1. The crystal structure of CNF<sub>Y</sub> from *Y. pseudotuberculosis*.**

- A Domain boundaries and sequence motifs mapped to the sequence of CNF<sub>Y</sub>.
- B Cartoon representation of CNF<sub>Y</sub>, colored according to domain boundaries determined with PISQRD (Aleksiev *et al*, 2009). Dark blue: domain D1, cyan: domain D2, dark green: domain D3, yellow: ADP-ribosyltransferase-like domain D4, pink: deamidase domain D5. Other colors indicate the position of sequence motifs that have been identified in *E. coli* CNF1, namely light blue: p37LRP/67LR receptor-binding motif, red: hydrophobic stretches predicted to form membrane-inserting  $\alpha$ -helices, orange: cleavage site, magenta: main Lu/BCAM receptor-binding motif. The positions of N- and C-terminus are indicated by N and C, respectively.
- C Surface representation of CNF<sub>Y</sub> as seen from two different orientations with respect to (B). Note that the cleavage site between D3 and D4 (orange) as well as the deamidase active site in D5 are partially blocked in the structure of full-length CNF<sub>Y</sub>. The C-terminal domain D5 interacts mainly with D3 (610 Å<sup>2</sup>), which partially hides the catalytic site of D5, but it interacts only weakly with D4 (380 Å<sup>2</sup>), which itself establishes an extensive interface with D1 (1,390 Å<sup>2</sup>) by mainly hydrophilic interactions (17 hydrogen bonds and 6 salt bridges).

Use of CNF<sub>Y</sub>-TEM derivatives further revealed that all deletions of or within domain D1 abolished translocation of the active domain into the host cell cytoplasm when added to host cells (Fig 3A), although CNF<sub>Y</sub>  $\Delta$ 39–134 and CNF<sub>Y</sub>  $\Delta$ 39–426 derivatives were still able to bind host cells (Fig 2D) and associate with the late endosome (Fig 4). This demonstrated that domain D1 is an important component of the translocation machinery but not essential for host cell binding and endocytosis.

For *E. coli* CNF1, two hydrophobic  $\alpha$ -helices have been predicted between residues 350–372 and 387–412, which are believed to insert into the endosomal membrane after charge neutralization of a conserved acidic patch in the connecting loop (D373, D379, E382, and E383) (Pei *et al*, 2001). However, the respective segments do not fold into the predicted  $\alpha$ -helices in CNF<sub>Y</sub> but adopt mostly loop-like structures with a helical part at their C-terminus (Figs 1B and EV2), which may be a consequence of the neutral pH at which CNF<sub>Y</sub> has been crystallized here. In line with previous work on *E. coli* CNF1, site-directed mutagenesis of the acidic residues E382 and E383 in the acidic patch to lysines did not abolish the enzymatic activity of the toxin derivative when added to host cell lysates (Appendix Fig S2). The CNF<sub>Y</sub> E382K/E383K variant was still secreted but failed to activate RhoA and induce multinucleation (Appendix Fig S2). This supported previous assumptions that acidic residues in the connecting loop are important for translocation (Pei *et al*, 2001).

Importantly, domain D1 alone does not seem to be sufficient for the translocation process, as the C-terminally truncated derivative CNF<sub>Y</sub> 1–443, consisting of domains D1–D2, was unable to translocate the  $\beta$ -lactamase TEM cargo protein into the cytosol, deamidate RhoA in host cells and induce multinucleation (Fig 3), despite the fact that it was internalized and reached late endosomes (Fig 4). This indicated that the translocation machinery of CNFs requires additional components for functionality.

**Domain D2 is a receptor-binding domain of CNFs**

Unlike the N-terminal  $\alpha$ -helix (residues 5–18), which is an integral part of the helical bundle that dominates domain D1, residues 23–134 seem to establish a separate structural building block (domain D2) that protrudes from the mostly  $\alpha$ -helical subunit, potentially suggesting its insertion during evolution (Fig 1B). It consists of a three-stranded anti-parallel  $\beta$ -sheet flanked by  $\alpha$ -helices at the side facing D1 and by several surface-exposed loops at the other. One solvent-exposed loop contains residues 53–75, a segment that has previously been implicated in host cell binding of *E. coli* CNF1 to receptor p37LRP/67LR (Figs 1B and EV2) (Fabbri *et al*, 1999; Chung *et al*, 2003; Kim *et al*, 2005). It is hence conceivable that this domain represents the N-terminal receptor-binding domain of CNFs. The

solvent-exposed loop interacts with residues 112–116 at the surface of D2, such that these segments together may establish a receptor-binding interface of the CNFs (Fig EV2). There are ten amino acid changes between CNF1 and CNF<sub>Y</sub> within these regions (Fig EV1), which may account for the distinct receptor specificity of both toxins (Blumenthal *et al*, 2007).

As outlined above, host cell binding and colocalization studies with truncated CNF<sub>Y</sub> derivatives showed that the D1–2 (1–443) fragment was able to bind host cells (Fig 2D) and reached the late endosomes (Fig 4), indicating that this truncated version of CNF<sub>Y</sub> indeed includes a cell receptor-binding site similar to CNF1 (Fabbri *et al*, 1999; Chung *et al*, 2003; Kim *et al*, 2005). However, this also demonstrates that CNF<sub>Y</sub>, unlike previous work with CNF1 suggests (Piteau *et al*, 2014; Reppin *et al*, 2017), does not require a second recognition site in the C-terminal region to be endocytosed by host cells.

**Domain D3 is an essential part of the translocation apparatus of CNFs**

The third domain, D3 (residues 425–529), is reminiscent of an incomplete  $\beta$ -barrel, containing six anti-parallel strands in CNF<sub>Y</sub>. No homologous structures could be discovered with DALI. Because a fragment consisting only of domains D1–2 (CNF<sub>Y</sub> 1–443) was not able to translocate the fused TEM- $\beta$ -lactamase into the host cell cytosol whereas the D1–3 fragment (CNF<sub>Y</sub> 1–526) was (Fig 3A), D3 is obviously essential for intoxication. D1–3 translocated TEM- $\beta$ -lactamase with the same efficiency as full-length CNF<sub>Y</sub> (Appendix Fig S3), and although it is unclear whether the  $\beta$ -lactamase was released from D1–3 or only exposed on the cytosolic side from the endosomal membrane, these experiments clearly demonstrated that the translocation apparatus of CNFs consists of the three domains D1–3. The importance of D3 is also highlighted by the fact that (i) the N-terminus of *Pasteurella multocida* exotoxin PMT possesses high homology to D1–3 of CNF<sub>Y</sub>, whereby cargo delivery includes proteolytic cleavage downstream of the prospective D3 domain, and (ii) the finding that a hybrid toxin consisting of this N-terminal fragment (residues 1–505) of PMT and the ADP-ribosylating domain of DT was able to intoxicate cells (Bergmann *et al*, 2013; Clemons *et al*, 2018).

**The cleavage site between D3 and D4 is partially shielded in full-length CNF<sub>Y</sub>**

The imperfect  $\beta$ -barrel domain D3 and the following domain D4 are connected via a linker that is partially shielded by the C-terminal deamidase domain D5 in the structure of full-length CNF<sub>Y</sub> (Fig 1C). In CNF1, this linker is cleaved between residues 532–544 to release the D4–5 subunit into the host cell cytosol (Knust *et al*, 2009),




Figure 2.

**Figure 2. Synthesis, secretion, and host cell binding of N- and C-terminal deletion variants of CNF<sub>γ</sub>.**

- A Schematic overview of marker-tagged CNF<sub>γ</sub> deletion variants.
- B 3xFlag-tagged CNF<sub>γ</sub> deletion variants were expressed in *Y. pseudotuberculosis* YP147 ( $\Delta$ cnf<sub>γ</sub>) from plasmids under control of their own promoter and were detected in whole cell extracts using an anti-Flag antibody.
- C To test secretion of the CNF<sub>γ</sub> variants, full-length CNF<sub>γ</sub> and different N- and C-terminally deleted variants fused to  $\beta$ -lactamase (TEM) were expressed in *Y. pseudotuberculosis* YP147 ( $\Delta$ cnf<sub>γ</sub>).  $\beta$ -lactamase activity in the culture supernatant was subsequently measured using nitrocefin as substrate. The data represent the mean  $\pm$  SD of three independent experiments, carried out in triplicates.
- D HEp-2 cells remained untreated or were incubated with 20  $\mu$ g/ml of whole cell extract of *Y. pseudotuberculosis* expressing full-length CNF1, CNF<sub>γ</sub> or the N- or C-terminally deleted toxin variants at 37°C for 4 h. The cells were thoroughly washed, pelleted, lysed and the toxin variants bound to the cells were identified by western blotting using an anti-Flag antibody.

Source data are available online for this figure.

suggesting that the respective segment must become solvent-exposed in the course of host cell intoxication to be accessible to proteases. As outlined below, this likely is linked to unfolding during translocation of the D4–5 segment into the cytosol of the host cell.

In order to identify amino acids that are important for the cleavage step, we introduced mutations within this linker. The recombinant CNF<sub>γ</sub> mutant proteins were both able to bind to host cells (Fig 6A), but only the CNF<sub>γ</sub> I535L/P536A/V537G mutant with changes in the N-terminal part of the linker (CNF<sub>γ</sub> mut1), but not the CNF<sub>γ</sub> variant I535L/P536A/V537G/F539L/D541A/K542A (CNF<sub>γ</sub> mut2) was secreted by *Y. pseudotuberculosis* in the absence of cell lysis (Fig 6C and D) and led to multinucleation of HEp-2 cells (Fig 6B). Although both CNF<sub>γ</sub> mutant proteins deamidated RhoA in cell lysates (Fig 6F), indicating proper folding and full activity, only CNF<sub>γ</sub> mut1 promoted translocation into the host cell cytoplasm and was able to deamidate RhoA when added to host cells (Fig 6E). However, this was not the case for CNF<sub>γ</sub> mut2, suggesting that this variant is unable to escape the endosome.

In summary, this indicated that amino acids important for proper processing are located at the C-terminal end of the linker.

**Domain D4 has structural similarity to ADP-ribosyl transferases**

Sequence analysis places the fourth domain D4 (residues 530–700) into the DUF4765 family, a building block that is also found in a number of other uncharacterized bacterial proteins (Fig EV3A). Surprisingly, structure similarity searches reveal distant but significant homology to ADP-ribosyl transferase (ART) domains (Appendix Table S2), which are widespread in protein toxins (Fieldhouse & Merrill, 2008). This similarity is exemplified by two examples (*Clostridium perfringens* iota toxin, PDB entry 4H03 (Tsurumura *et al*, 2013); *Pseudomonas aeruginosa* ExoA, PDB entry 2ZIT (Jørgensen *et al*, 2008)) shown in Figs 5B and EV3.

In order to gain further insight into the function of domain D4, which is translocated and released together with the catalytic domain, we analyzed two mutant variants harboring internal deletions of amino acids 526–719 or 526–699. However, both variants did not deamidate RhoA in host cell lysates, indicating that these mutant proteins failed to fold properly (Appendix Fig S4). Since structure similarity searches revealed distant homology to the ADP-ribosyltransferase (ART) domains, we hypothesized that CNFs may possess a second, previously unrecognized enzymatic function encoded in D4. The active sites of ARTs fall into two groups, the RSE- for a conserved arginine-serine-glutamate active site motif and the HYE-ARTs for histidine-tyrosine-glutamate (Cohen & Chang, 2018). The ART-like domain D4 contains arginine,

glutamate, and histidine at the respective positions instead (R599, E639, H676), which could, in principle, support similar chemistry and are, with the exception of the CNF-specific H676, highly conserved in other DUF4765-containing proteins (Fig EV3A). However, exchange of CNF<sub>γ</sub> E639, which is in the comparable position of the conserved glutamate of bacterial ARTs, to alanine or glutamine had no effect on CNF<sub>γ</sub> function (Appendix Fig S5). Moreover, we could not detect binding of the ART cosubstrate NAD<sup>+</sup> to a CNF<sub>γ</sub> fragment consisting of domains D4–5 in microscale thermophoresis titration experiments. The inability to bind NAD<sup>+</sup> may be a consequence of the altered geometry of the potential NAD<sup>+</sup> binding site of D4, which leads to a shallower hypothetical NAD<sup>+</sup> binding site and to clashes when NAD<sup>+</sup> is superimposed from the two examples mentioned above (Fig EV3B).

**Domain D5 is highly similar to the deamidase domain of CNF1**

The C-terminal catalytic deamidase domain D5 is linked to D4 via the unstructured residues P701-L717 (Fig 1B). These belong to the postulated binding epitope for the Lu/BCAM host receptor of CNF1 (Piteau *et al*, 2014), and their flexibility may be a requirement for receptor binding by the toxin.

The D5 domain is very similar to the respective domain of *E. coli* CNF1 (PDB entry 1HQ0 (Buetow *et al*, 2001); 1.8 Å rmsd over 295 residues, 59% sequence identity), featuring a central  $\beta$ -sandwich with shielding  $\alpha$ -helices on both sides (Figs 1B and 5C). The active site employs the conserved cysteine/histidine couple C866/H881 (Hoffmann *et al*, 2004), which lies in a crevice on the surface of the domain and deamidates a conserved glutamine in the switch-II region of the targeted Rho GTPases. In agreement, only the full-length CNF<sub>γ</sub> protein was able to activate the Rho GTPase RhoA (Fig 3B), resulting in the induction of polynucleation in living cells (Fig 3C), whereas all protein variants with deletions of the C-terminal domain D5 eliminated toxicity (Fig 3B and C). This is consistent with studies showing that the C-terminal 300 amino acids (709–1,014) of the related *E. coli* CNF1 protein are important for its activity (Koornhof *et al*, 1999; Zhang *et al*, 2018; Fabbri *et al*, 2019). Neither the deletion nor site-directed mutagenesis of the catalytic domain affected secretion, host cell binding, or protein translocation (Figs 2B and C, and 3A), indicating that the sole role of the C-terminal domain is the targeting and modification of Rho GTPases.

While the crevice is nearly identical between CNF<sub>γ</sub> and CNF1, differences exist between two loops at the periphery of the active site, namely residues 961–970 and residues 996–1,004 (Figs 5C and EV1). It is not clear if these deviations are sufficient to explain the slightly altered preferences for various Rho GTPases that have been described for both CNFs (Hoffmann *et al*, 2004; Schweer *et al*,

2013), but amino acids in one of these loops (residues 961–970) have previously been implicated in substrate recognition of CNF $\gamma$  and CNF1 (Hoffmann *et al*, 2007). Interestingly, a similar deamidation domain is also found in *Burkholderia* lethal factor 1 (BLF1), despite extremely low sequence similarity (Fig 5C; PDB entry 3TU8; (Cruz-Migoni *et al*, 2011); 3.5 Å rmsd over 169 residues, 7% sequence identity). BLF1 is a single-domain toxin that deamidates a glutamine residue in translation initiation factor eIF4A. In addition,

several other toxins including e.g. *Bordetella pertussis* dermonecrotizing toxin DNT are predicted to contain similar deamidase domains (Ho *et al*, 2018).

**The D4–5 fragment of CNF $\gamma$  contains a receptor-binding site sufficient for endosomal uptake**

We further characterized the properties of the recombinant D4–5 domains (residues 526–1,014), which together constitute the C-




Figure 3.



**Figure 3. Translocation of the deletion variants of CNF<sub>Y</sub> and their influence on RhoA activation, actin rearrangements and multinucleation of host cells.**

- A HEP-2 cells were incubated with 20 µg/ml of whole cell extract of *Y. pseudotuberculosis* expressing full-length CNF<sub>Y</sub> or the N- or C-terminally deleted toxin variants fused to β-lactamase (TEM) at 37°C for 4 h. Cleavage of the reporter dye CCF4-AM was used to visualize toxin delivery. After cell entry, CCF4-AM is rapidly converted into the negatively charged form CCF4, which is retained in the cytosol and emits a green fluorescence signal (530 nm). In the presence of translocated β-lactamase fusion proteins, CCF4-AM is cleaved, and disruption of FRET results in blue fluorescence (450 nm). Scale bar: 20 µm.
- B Left upper and right panel: HEP-2 cells remained untreated or were incubated with 20 µg/ml of whole cell extract of *Y. pseudotuberculosis* expressing full-length CNF<sub>Y</sub> or the N- or C-terminally deleted toxin variants for 4 h. Cells were lysed and the deamidation of RhoA was analyzed by the shift of the modified Rho GTPase band in SDS-PAGE gels; left lower panel: HEP-2 cells were lysed and the cell extracts were incubated with full-length CNF<sub>Y</sub> or the N-terminally deleted toxin variants for 4 h. The deamidation of RhoA in the cell extracts was analyzed by the mobility shift of the modified Rho GTPase on SDS-PAGE after detection with anti-RhoA antibodies.
- C HEP-2 cells were incubated with 20 µg/ml of whole cell extract of *Y. pseudotuberculosis* expressing full-length CNF<sub>Y</sub> or the N- or C-terminally deleted toxin variants for 24 h. The cell nuclei were stained with DAPI (blue) and the actin cytoskeleton was stained using FITC-phalloidin (green). The formation of large, multinuclear cells was observed by fluorescence microscopy and the formation of thick actin stress fibers and membrane actin folding were only observed with CNF<sub>Y</sub>-treated cells. The white scale bar is 40 µm. Cells incubated with extracts of YP147 (*ΔcnfY*) harboring the empty expression vector were used as negative controls.

Source data are available online for this figure.

terminal fragment that is translocated into the host cell cytoplasm after cleavage of CNF<sub>Y</sub> (Fig EV4). Although catalytically active when added to host cell extracts, D4–5 is unable to deamidate RhoA when added to host cells (Fig EV4E–D). This suggested that it was either not taken up into the host cell or unable to escape the endosome to reach the cytoplasm. Cell binding assays demonstrated, however, that the D4–5 fragment (CNF<sub>Y</sub> 526–1,014), similar to D1–3 (CNF<sub>Y</sub> 1–526), specifically interacts with host cells (Figs 2D, and EV4C and Appendix Fig S6). A parallel analysis of D3–5 (CNF<sub>Y</sub> 426–1,014), also missing the N-terminal receptor-binding domain, confirmed these results (Fig EV4C). This indicated the presence of a second host cell binding site in the C-terminal region, which is strongly supported by the fact that N-terminal deletions missing parts of D1–2 (CNF<sub>Y</sub> Δ39–426) are still able to promote cell binding and endosomal uptake as indicated by colocalization studies (Figs 2D and 4).

In *E. coli* CNF1, the binding site for the Lu/BCAM receptor was shown to include amino acids 720–730 of the catalytic domain (Reppin *et al*, 2017). The respective segment is significantly different in CNF<sub>Y</sub> (Fig EV1), which may explain why CNF<sub>Y</sub> does not interact with Lu/BCAM. Instead, a recent study has shown that a C-terminal fragment of CNF<sub>Y</sub> (residues 709–1,014) employs glycosaminoglycans as receptors and is sufficient for endosomal uptake (preprint: Kowarschik *et al*, 2020), in line with the observations made here. Thus CNF<sub>Y</sub>, similar to CNF1 (Piteau *et al*, 2014; Reppin *et al*, 2017), contains two distinct host cell binding sites, one each at the N- and C-terminus. In CNF<sub>Y</sub>, these binding sites enable endosomal uptake independently of each other, and the presence of two receptor-binding sites might broaden the range of targeted cells or may increase host cell binding affinity.

#### **The D4–5 segment adopts a different conformation and shows increased deamidase activity after cleavage from full-length CNF<sub>Y</sub>**

Previous work with *E. coli* CNF1 demonstrated that translocation releases a fragment consisting of the ART-like domain D4 and the deamidase domain D5 into the cytosol of host cells (Knust *et al*, 2009). This prompted us to crystallize the respective segment of CNF<sub>Y</sub>, leading to a structure in which linker residues V702–L717 again were too flexible to be traced and in which the two domains adopt a different relative orientation with respect to the full-length protein. Whereas D4 and D5 interacted only weakly in the complete toxin, they now engage in a large interface (1,100 Å<sup>2</sup>), whereby the active site crevice of D5 is extended by D4 and becomes fully solvent-exposed (Fig 7A). To reach this position, domain D4 has to rotate by more than 140°, which can probably only be achieved


after cleavage from D1–3 and through the flexibility of the linker connecting both domains. The contact area between both domains in the free D4–5 subunit overlaps largely with that of D3–5 in the full-length structures such that both conformations are mutually exclusive, i.e. the D4–5 subunit cannot adopt the conformation observed in the free state when it is bound to D1–3.

The finding that the active site within domain D5 becomes more exposed in the recombinant D4–5 fragment suggested that the presence of domains D1–3 may repress the deamidase activity of CNF<sub>Y</sub> and that cleavage of the D4–5 fragment is required to rearrange, liberate and activate the catalytic unit. To test this hypothesis, we incubated equal amounts of purified CNF<sub>Y</sub> 1–1,014 (D1–5) and CNF<sub>Y</sub> 526–1,014 (D4–5) with host cell extracts or recombinant RhoA and analyzed the deamidation of RhoA in gel-shift assays and with proteomic methods. As shown in Fig 7B and C, RhoA deamidation by CNF<sub>Y</sub> 526–1,014 (D4–5) protein was indeed significantly faster than by the full-length protein, indicating that the domain rearrangement seen in the D4–5 fragment enhances the deamidase activity and that the full-length toxin is in an autoinhibited state with respect to this activity.

## Discussion

Here, we show that CNF<sub>Y</sub> and related CNFs consist of five individual structural building blocks that enable the different steps of the intoxication process, namely secretion, cell attachment, entry, translocation and enzymatic activity. The three N-terminal domains D1–3 all possess novel folds and constitute the secretion and membrane translocation unit, whereas the two C-terminal domains D4–5 form the toxicity-mediating unit of the toxin. We further show that the D1–3 unit is sufficient to transport cargo proteins such as β-lactamase into the cytosol of host cells. Strikingly, both the Rho deamidation and β-lactamase activity were preserved when the reporter was fused to the C-terminal end of the full-length protein (Fig 3), indicating that the secretion and transport module of the CNF<sub>Y</sub> protein are very robust and insensitive to C-terminal extensions, making it an attractive tool for drug delivery.

The molecular mechanisms by which domains D1–3 promote the delivery of the cargo from the bacterial to the host cell cytosol are still unknown. However, considering the compact arrangement of CNF<sub>Y</sub>, it is likely that bacteria secrete these toxins and host cells endocytose them as a monolithic compact structure. In fact, the CNF<sub>Y</sub> toxin has recently been identified on the surface of outer



**Figure 4. Localization of the N- and C-terminal deletion variants of CNF $\gamma$  in the late endosome.**

HEp-2 cells were incubated with 20  $\mu$ g/ml of whole cell extract of *Y. pseudotuberculosis* expressing full-length CNF $\gamma$ , N- or C-terminal deletion variants fused to GFP (green) for 90 or 180 min. Cells were fixed and processed for fluorescence microscopy. The red fluorescent signal represents late endosomes (CellLight Late Endosomes-RFP (Rab7a)). Nuclei were stained with DAPI (blue). A merged image of the different channels is shown, and smaller images are magnified views of boxed areas. White scale bar is 10  $\mu$ m.

membrane vesicles (OMVs) isolated from *Y. pseudotuberculosis* culture supernatants (Monnappa *et al*, 2018). While this could indicate that the toxin might be predominantly delivered into endosomes by OMVs, our data further show that the purified CNF $\gamma$  toxin also interacts with and is efficiently internalized into host cells on its own. This suggests that the toxin is also directly secreted by the

bacterial cell and/or exposed on the OMVs to promote contact with target cells.

The data presented here further show that the cellular toxin uptake process not only requires segments identified for receptor binding in D2 and for translocation in D1, but also the imperfect  $\beta$ -barrel domain D3. It is interesting to note that D1 is, due to its




Figure 5.

**Figure 5. Structural homology of the CNF $\gamma$  toxin and domain organization of toxins with a CNF-like translocation apparatus.**

A Side-by-side comparison of CNF $\gamma$  and nigrifoxin. Nigrifoxin is a toxin of crustaceans and insects. The translocation domain of nigrifoxin [PDB entry 5M41, (Labreuche et al, 2017)] and domain D1 of CNF $\gamma$  show partial structural similarity (highlighted areas). This similarity was identified with DALI (Holm & Rosenström, 2010) which was also used to align both structures.

B The ART-like domain D4 of CNF $\gamma$ . Essential residues of canonical ARTs are not conserved in CNF $\gamma$  (RSE-ARTs exemplified by *C. perfringens* iota toxin, PDB entry 4H03 (Tsurumura et al, 2013); HYE-ARTs exemplified by *P. aeruginosa* ExoA, PDB entry 2ZIT (Jørgensen et al, 2008); carbon atoms of NAD<sup>+</sup> shown in black).

C The deamidase domain D5 of CNF $\gamma$ . C866 and H881 form a conserved catalytic dyad also found in the deamidase domain of *E. coli* CNF1 [PDB entry 1HQ0, (Buetow et al, 2001)] and *Burholderia pseudomallei* lethal factor BLF1 [PDB entry 3TU8, (Cruz-Migoni et al, 2011)].




Figure 6.

**Figure 6. Characterization of mutants in the linker region connecting domain D3 and D4.**

- A HEP-2 cells were incubated with 20  $\mu\text{g/ml}$  of whole cell extract of *Y. pseudotuberculosis* expressing CNF $_{\gamma}$ , the toxin variant mut1: CNF $_{\gamma}$ I535L/P536A/V537G or mut2: CNF $_{\gamma}$ I535L/P536A/V537G/F539L/D541A/K542A fused to TEM or no CNF $_{\gamma}$  protein (empty vector) for 4 h. Cells were lysed and the binding of the different CNF $_{\gamma}$  proteins to HEP-2 cells was analyzed by immunoblotting.
- B HEP-2 cells were incubated with 20  $\mu\text{g/ml}$  of whole cell extract of *Y. pseudotuberculosis* expressing CNF $_{\gamma}$ , the toxin variant mut1: CNF $_{\gamma}$ I535L/P536A/V537G or mut2: CNF $_{\gamma}$ I535L/P536A/V537G/F539L/D541A/K542A or no CNF $_{\gamma}$  protein (empty vector). The cell nuclei were stained with DAPI (blue) and the actin cytoskeleton was stained using FITC-phalloidin (green). The results indicated the formation of polynucleated cells and stress fibers only in cells treated with CNF $_{\gamma}$  and CNF $_{\gamma}$ I535L/P536A/V537G. The white scale bar is 20  $\mu\text{m}$ .
- C Nitrocefin (2 mM) was added to the supernatant from 25°C overnight *Yersinia* cultures expressing the indicated CNF $_{\gamma}$  derivatives to determine  $\beta$ -lactamase activity by measuring changes in absorbance at 390 nm (yellow) and 486 nm (red). The data represent the mean  $\pm$  SD of three independent experiments, carried out in triplicates.
- D The viability of *Y. pseudotuberculosis* YPIII expressing the indicated CNF $_{\gamma}$  derivatives was assessed in equalized bacterial cultures using the BacTiter-Glo Microbial Cell Viability Assay kit (Promega). The data represent the mean  $\pm$  SD of three independent experiments, carried out in triplicates.
- E HEP-2 cells treated with 20  $\mu\text{g/ml}$  of whole cell extract of *Y. pseudotuberculosis* expressing indicated CNF $_{\gamma}$  variants for 4 h were lysed and the deamidation of RhoA was analyzed by the mobility shift of the modified RhoA GTPase detected by immunoblotting.
- F The activity of the CNF $_{\gamma}$  derivatives was tested by analyzing the deamidation of RhoA in HEP-2 cell lysates by the mobility shift of the modified GTPase detected by immunoblotting.

Source data are available online for this figure.




mostly  $\alpha$ -helical character, reminiscent of the translocation machinery of other toxins including that of the diphtheria toxin DT. DT, CNFs, and several other AB-type toxins contain two hydrophobic stretches that are believed to fold into  $\alpha$ -helices and insert into the endosomal membrane after charge neutralization of surrounding acidic residues (Pei *et al*, 2001; Orrell *et al*, 2017). In CNF $_{\gamma}$ , the respective residues 350–372 and 387–412 were not found in the predicted  $\alpha$ -helical structure (Fig 1B). However, since the crystal structures presented here have been obtained at neutral pH, it is conceivable that this region undergoes refolding during endosomal acidification. While the precise molecular mechanism of the complex translocation process of CNF $_{\gamma}$  is still unclear (Pitard & Malliavin, 2019), work with DT suggests that the catalytic subunit of this toxin is unfolded in the translocation process (Murphy, 2011). The fact that (i) translocation in CNFs also involves two hydrophobic motifs interrupted by acidic residues and (ii) the observation that a sequence that gets cleaved to release the catalytic unit (D4–5) of CNF (residues 532–544) is not accessible in the full-length structure (Fig 1C) may hint at a similar unfolding in the CNFs. In this respect, the similarity of parts of CNF $_{\gamma}$ 's D1 domain to the putative translocation domain of nigrifoxin (Fig 5A) (Labreuche *et al*, 2017) is interesting, because the translocation domain of this toxin does not contain hydrophobic  $\alpha$ -helices. This could indicate that the translocation process occurs through several steps that involve different parts of the translocation machinery, most of which are not shared between the CNFs and nigrifoxin.

Sequence searches in the UniRef50 database (Suzek *et al*, 2015) revealed that large sections of the D1–3 domain of CNF $_{\gamma}$  are also found in a number of un- or less characterized bacterial proteins, suggesting that these proteins are toxins that apparently utilize a similar secretion and translocation device for their catalytic domains (Fig 8). For example, about 530 amino acids of the N-terminus of CNF $_{\gamma}$  share between 30–50% sequence identity to the N-terminus of *Pasteurella multocida* toxin PMT (Bergmann *et al*, 2013). Moreover, members of a group consisting of 372 proteins with approximately 900 residues each were found to possess a canonical RSE-type ART-domain at their C-terminus (represented by UniProt entry A0A0P9UH04 from *Pseudomonas syringae* *pv. maculicola*) in addition to a CNF-like translocation apparatus. A second group of 206 proteins with more than 1,000 residues contains a C-terminal

glycosyltransferase (represented by UniProt entry A0A0N8SZE6 from *Pseudomonas syringae* *pv. syringae*). Since the C-termini of these proteins differ from CNF $_{\gamma}$  (Fig 8), it is likely that the toxins consist of individual modules that have been shuffled in the course of evolution. This aligns with a recent analysis of the distribution of CNF-like deamidase domains, which are also found at different positions within the sequence of other toxins or as stand-alone proteins (Cruz-Migoni *et al*, 2011; Ho *et al*, 2018).

The finding that the DUF4765 domain D4 shows similarity to ADP-ribosyltransferases was surprising and led us to investigate if the released D4–5 may possess an additional and previously unrecognized enzyme activity that may contribute to the toxicity of CNFs. However, the observation that CNF $_{\gamma}$  toxicity strictly depended on the activity of the deamidase D5 domain whereas mutations of the potential/suggested NAD $^{+}$  binding domain within D4 had no effect (Appendix Fig S5), together with the fact that we could not detect NAD $^{+}$  binding in biophysical experiments, speaks against such an additional activity. On the other hand, the NAD $^{+}$  affinity of some ADP-ribosyl transferases is very low. This is exemplified by cholera toxin, where a  $K_D$  of  $4.0 \pm 0.4$  mM has been determined (Galloway & van Heyningen, 1987). Alternatively, the grossly different and mutually exclusive relative orientations of the D4 and D5 domains in the free D4–5 subunit with respect to the full-length CNF $_{\gamma}$  structure (Fig 7) could suggest that D4 may have a regulatory role. On the one hand, the finding that the active site becomes solvent-accessible and that the crevice leading to the active site of D5 becomes extended by parts of D4 (Fig 7) could fine-tune the deamidase function of D5 with respect to general activity levels or substrate specificity toward RhoA, Rac1 or Cdc42. On the other hand, D4 could contribute to localizing the catalytic unit within the host cell by promoting access to membrane-associated Rho GTPases. In fact, CNFs act predominantly on Rho GTPases bound to GTP, a form essentially found at the cytoplasmic face of the host cell membrane (Boquet, 2001). Clearly, the importance of D4 merits future studies.

In summary, the data presented here provide insight into the full-length and released active D4–5 structure, and they illustrate the importance of the individual building blocks of CNFs and related exotoxins. This not only forms the basis for the detailed analysis of the molecular secretion and transport mechanism, but also enables the rational design of the transport module as a toxin-based cargo




**Figure 7. Structure and deamidation activity of the free D4–5 subunit of CNF<sub>γ</sub>.**

A Crystal structure of the free D4–5 subunit. Note the different relative orientations of domains D4 and D5 with respect to the structure of full-length CNF<sub>γ</sub> (top, thin gray lines). The domain D4 forms a large interface area (1,100 Å<sup>2</sup>) with the catalytic domain D5 involving several polar interactions (8 hydrogen bonds and 8 salt bridges), whereby the active crevice is extended and fully solvent-exposed as can be seen in the right surface plot at the bottom of the panel. The hypothetical NAD<sup>+</sup> binding site of the ART-like D4 domain is located on the opposite face (left surface plot). Note that the deamidase active site of domain D5, unlike in the full-length structure (Fig 1), is fully accessible and that its extended shape is also determined by domain D4.

B Comparative analysis of RhoA activation in HEP-2 cell lysate by CNF<sub>γ</sub> and the recombinant D4–5 protein. Purified CNF<sub>γ</sub> or the D4–5 fragment (1 μM) was added to extracts of HEP-2 cells and incubated for 10, 20, 30, or 60 min. Deamidation of RhoA was analyzed by the shift of the modified Rho GTPase band in SDS–PAGE gels after detection with anti-RhoA antibodies.

C Comparative analysis of recombinant RhoA deamidation by CNF<sub>γ</sub> and the D4–5 fragment. Recombinant RhoA was incubated with purified CNF<sub>γ</sub> or the D4–5 fragment and samples were separated by SDS–PAGE after the indicated times before subjecting to trypsin digestion and quantification of deamidation of Q63 by mass spectrometry. Error bars represent standard deviations of triplicate measurements.

Source data are available online for this figure.



**Figure 8. Architecture of bacterial toxins with a CNF-like translocation apparatus.**

Shown is the architecture of CNF<sub>γ</sub>, *Pasteurella multocida* toxin PMT and two uncharacterized proteins from *Pseudomonas syringiae*. The released fragment of PMT contains three domains of which C1 is required for membrane binding, the C2 domain has an unknown function, and the C3-domain activates heterotrimeric G-proteins by deamidation. The two *Pseudomonas syringiae* proteins AOAOP9UH04 and AOA0N8SZE6 represent uncharacterized toxins that encode catalytic domains of the indicated type. While sequence alignments unequivocally reveal a CNF-like imperfect β-barrel in PMT, the presence of this domain in the *P. syringiae* toxins is less obvious.

delivery tool for cytosolic drug/therapeutics delivery and the structure-guided development of inhibitors of CNF-like virulence factors.

## Materials and Methods

### Bacterial strains, cell lines, plasmids, and growth conditions

All bacterial strains and plasmids used in this study are listed in Appendix Table S3. All oligonucleotide primers used for cloning are listed in Appendix Table S4. *E. coli* strains were grown in Luria-Bertani (LB; Becton Dickinson) broth at 37°C. *Yersinia* strains were aerobically grown in LB at 25°C or 37°C. Other media used for bacterial growth were brain–heart infusion broth (BHI) (Gibco) and Double Yeast Tryptone medium (DYT) (Gibco). Cultures were supplemented with 30 μg/ml kanamycin (Kan) or chloramphenicol (Cm) where necessary. HEP-2 cells (ATCC CCL-23) were grown at 37°C, 5% CO<sub>2</sub> in RPMI (Gibco) supplemented with 7.5% newborn calf serum (NCS; Sigma).

### Antibodies

The following antibodies have been used in this study: anti-RhoA from Biomol No. NB-26007 and Abcam No. ab54835; anti-actin from Sigma No. A2228-100UL, anti-Flag-M2 from Sigma No. F3165-1MG, anti-β-lactamase (TEM) from Abcam No. ab12251, anti-GFP from Sigma No. 11814460001, and anti-IgG from Cell Signalling No. 7076S.

### Cloning, expression, and purification of recombinant CNF<sub>γ</sub> variants

For crystallography purposes, truncated constructs were generated comprising a fragment lacking the catalytically active C-terminal domain (CNF<sub>γ</sub>1–704), a construct containing both C-terminal

domains D4–5 (CNF<sub>γ</sub>526–1,014) and another containing only the catalytic domain D5 (CNF<sub>γ</sub>720–1,014). For crystallization of the full-length protein, a construct containing the inactive C866S variant of CNF<sub>γ</sub> was produced.

The coding sequences of D4–5 (CNF<sub>γ</sub>1–704) and D5 (CNF<sub>γ</sub>720–1,014) were both cloned into pET28c containing sequences coding for an N-terminal hexa-histidine tag and a thrombin protease cleavage site. The constructs were transformed into *E. coli* BL21 (DE3) (CNF<sub>γ</sub>1–704) or Rosetta II (DE3) (CNF<sub>γ</sub>720–1,014). Native protein was expressed in lysogenic broth (LB) medium at 20°C after induction with 0.5 mM isopropyl-β-D-thiogalactopyranosid (IPTG) for 16–18 h (D1–4; CNF<sub>γ</sub>1–704) or 4 h (D5; CNF<sub>γ</sub>720–1,024) (5), respectively. Seleno-L-methionine (Se-Met)-labeled protein of CNF<sub>γ</sub>1–704 (D1–4) was expressed using M9 minimal medium.

After harvesting, the cell pellets were resuspended in lysis buffer (for D1–4/CNF<sub>γ</sub>1–704: 1 × PBS, 400 mM NaCl, 5 mM β-mercaptoethanol, 5 mM MgSO<sub>4</sub>, 10 mM imidazole; for D5/CNF<sub>γ</sub>720–1,014: 50 mM Tris/HCl pH 8.0, 400 mM NaCl, 5 mM imidazole) and lysed by sonification. After centrifugation the supernatant was mixed with 1 ml Ni-NTA resin pre-equilibrated with wash I buffer (D1–4/CNF<sub>γ</sub>1–704: 1 × PBS, 400 mM NaCl, 10 mM imidazole, 5 mM MgSO<sub>4</sub>, 5 mM β-mercaptoethanol; D5/CNF<sub>γ</sub>720–1,014: 50 mM Tris/HCl pH 8, 400 mM NaCl, 5 mM imidazole) and incubated for 1 h on an overhead-shaker at 4°C. After washing with wash I buffer and wash II buffer (D1–4/CNF<sub>γ</sub>1–704: 1 × PBS, 400 mM NaCl, 20 mM imidazole, 5 mM MgSO<sub>4</sub>, 5 mM β-mercaptoethanol; D5/CNF<sub>γ</sub>720–1,014: 50 mM Tris/HCl pH 8, 400 mM NaCl, 20 mM imidazole), elution of the protein was carried out with 12 × 1 ml of elution buffer (D1–4/CNF<sub>γ</sub>1–704: 1 × PBS, 400 mM NaCl, 250 mM imidazole, 5 mM MgSO<sub>4</sub>, 5 mM β-mercaptoethanol; D5/CNF<sub>γ</sub>720–1,014: 50 mM Tris/HCl, 250 mM NaCl, 250 mM imidazole). Buffer exchange and tag cleavage with thrombin (1:50 mg/mg) were achieved over night by dialysis at 4°C in wash I buffer. To remove cleaved His-Tag, uncleaved protein and the thrombin protease, 1 ml of Ni-NTA resin, and 5 ml of benzamidine-sepharose resin,

respectively, were mixed with the dialyzed protein solution. The collected flow-through predominantly contained pure protein. Further purification was achieved by size-exclusion chromatography. D1–4 (CNF<sub>Y</sub>1–704) was purified using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) pre-equilibrated in buffer containing 20 mM Tris pH 8.0, 150 mM NaCl, 5 mM DTT. D5 (CNF<sub>Y</sub>720–1,014) was purified using a HiLoad 16/600 Superdex 75 pg (GE Healthcare) pre-equilibrated in buffer containing 25 mM Tris pH 8.0, 100 mM NaCl. The proteins were then concentrated to 20 mg/ml, flash-frozen in liquid nitrogen and stored or directly used for crystallographic screens.

The gene encoding for the full-length protein of the CNF<sub>Y</sub> C866S variant was cloned into a modified pCOLA Duet-1 vector (Novagen) encoding for an N-terminal Strep-tag II and TEV protease recognition site (construct: CNF<sub>Y</sub> C866S). In the case of D4–5 (CNF<sub>Y</sub> 526–1,014), the insert was amplified from pCNF<sub>Y</sub>3xFlag as template so that the three C-terminal FLAG-epitopes were included in the insert and cloned into the same modified pCOLA Duet-1 vector that was also used for the full-length toxin (construct: pVP-CNF<sub>Y</sub>526-1014-3xFlag). Both proteins were heterologously expressed in *E. coli* BL21 (DE3) in ZYM-5052 auto-inducing medium (Studier, 2005) at 20°C for 20–24 h.

In the case of D4–5 (CNF<sub>Y</sub>526–1,014), the cell pellet was resuspended in a buffer containing 20 mM HEPES/NaOH pH 7.5, 300 mM NaCl, 2 mM TCEP, one tablet of complete EDTA-free protease inhibitor cocktail (Roche) and lysed by sonication. The protein was isolated from the supernatant after centrifugation for 1 h at 100,000 g using a self-packed 10 ml column with Strep-Tactin Superflow High Capacity resin (IBA) and eluted from the column with a single step of 5 mM d-desthiobiotin. The affinity tag was cleaved off with TEV protease (1:50 mg/mg) at 4°C overnight. Gel filtration was carried out using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) in 20 mM HEPES/NaOH pH 7.5, 300 mM NaCl, 2 mM TCEP. The peak fractions were concentrated to 5 mg/ml and flash-frozen in liquid nitrogen for crystallization screening.

For the full-length protein, the cell pellet was resuspended in a buffer containing 20 mM HEPES/NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP, one tablet of complete EDTA-free protease inhibitor cocktail (Roche) and lysed by sonication. The protein was isolated from the supernatant after centrifugation for 1 h at 100,000 g using a self-packed 10 ml column with Strep-Tactin Superflow High Capacity resin (IBA) and eluted from the column with a single step of 5 mM d-desthiobiotin. The affinity tag was cleaved off with TEV protease (1:50 mg/mg) at 4°C overnight. Gel filtration was carried out using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) in 20 mM HEPES/NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP. The fractions corresponding to the second peak in the chromatogram (elution volume 70–75 ml) were pooled and subjected to further size-exclusion chromatography on a Superdex 200 Increase 10/300 GL column (GE Healthcare) in the same buffer. The peak fractions were concentrated to 27.5 mg/ml and flash-frozen in liquid nitrogen for crystallization screening. All chromatographic steps were carried out using an Äkta Purifier system (GE Healthcare). The samples were analyzed by SDS–PAGE (12%), and protein concentrations were determined from the absorbances at 280 nM with the extinction coefficients as calculated by ProtParam (Gasteiger *et al*, 2003).

CNF<sub>Y</sub>-TEM fusion proteins were obtained in a similar manner after cloning into pET28a, overexpression in *E. coli* Rosetta II (DE3) and a two-step purification protocol involving Ni-NTA affinity and size-exclusion chromatography.

### Crystallization

Crystallization trials were set-up at room temperature with a HoneyBee 961 crystallization robot (Digilab Genomic Solutions) in Intelli 96-3 plates (Art Robbins Instruments) with 200 nl protein solution at different concentrations and 200 nl reservoir solution. Native D1–4 (CNF<sub>Y</sub>1–704) was crystallized in 0.1 M Tris pH 7.3–7.9, 0.2 M ammonium sulfate and 19–21% (*w/v*) PEG 5000 monomethyl ether. The Se-Met derivative of D1–4 (CNF<sub>Y</sub>1–704) was crystallized in 0.1 M tri-sodium citrate pH 5.9–6.2, 0.2 M ammonium acetate and 28–32% (*w/v*) PEG 4000. Macro-seeding was applied in order to obtain well-diffracting crystals. As all tested compounds for cryoprotection were not tolerated by the samples, the crystals were flash-cooled without any additional cryoprotection. The catalytic domain D5 (CNF<sub>Y</sub>720–1,014) yielded crystals in several PEG or ammonium sulfate containing conditions and the best diffracting crystals were obtained in 0.2 M ammonium fluoride with 20% (*w/v*) PEG 3350. Crystals were cryo-protected with either 25% glycerol or 100% Type A oil (Hampton Research) prior to flash freezing in liquid nitrogen. A single well-diffracting crystal of D4–5 (CNF<sub>Y</sub>526–1,014) was obtained in the presence of 1 mM ATP in a condition containing 0.24 M magnesium chloride, 22.5% (*w/v*) PEG 2000 monomethyl ether. The crystal was harvested after 130 days of growth and cryo-protected by addition of 10% (*v/v*) (2*R*,3*R*)-2,3-butanediol. A single crystal of sufficient diffraction quality of full-length CNF<sub>Y</sub>C866S was obtained in 1.4 M ammonium sulfate, 0.13 M lithium acetate, 0.1 M HEPES/NaOH pH 7.1. The crystal was harvested after 21 days of growth and after removal of satellite crystals cryo-protected by addition of 10% (*v/v*) (2*R*,3*R*)-2,3-butanediol.

### Data collection and processing

Data collection of native and Se-Met-derivatized D1–4 (CNF<sub>Y</sub> 1–704) was performed on beamline PXIII of the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) and BESSY BL14.1 (Helmholtz-Zentrum Berlin, Germany) (Mueller *et al*, 2015). High-resolution data of D5 (CNF<sub>Y</sub> 720–1,014) were recorded at beamline BL 14.2 of the BESSY II (Helmholtz-Zentrum Berlin, Germany). Datasets of domain D4–5 (CNF<sub>Y</sub> 526–1,014) and full-length CNF<sub>Y</sub>C866S were measured at beamline X06DA (PXIII) at the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland). Data processing was achieved either manually via the XDS software package (Kabsch, 2010) or by using the AutoPROC (Vonrhein *et al*, 2011) toolbox (Global Phasing) executing XDS (Kabsch, 2010), Pointless (Evans, 2006), and Aimless (Evans & Murshudov, 2013). All datasets were recorded at a temperature of 100 K.

### Structure determination, refinement, and model building

The structure of domain D1–4 (CNF<sub>Y</sub> 1–704) was solved by single anomalous dispersion (SAD) using data collected at the selenium absorption edge. The initial phases were calculated using AutoSol



(Terwilliger *et al*, 2009) and a partial model was generated running AutoBuild (Terwilliger *et al*, 2008), both components of the Phenix software package (Adams *et al*, 2010). The output model was analyzed in Coot (Emsley *et al*, 2010) and misplaced main chains were removed or corrected manually in order to obtain a reliable search model for the following molecular replacement procedures against the dataset of native D1–4 (CNF<sub>Y</sub> 1–704) and the full-length C866S variant. The structure of D5 (CNF<sub>Y</sub> 720–1014) was determined by molecular replacement using the structure of the catalytic C-terminal domain of CNF1 from *E. coli* (PDB: 1HQ0, (Buetow *et al*, 2001)) as search model. The structure of domain D4–5 (CNF<sub>Y</sub>526–1,014) was determined by molecular replacement using the structure of domain D5 (CNF<sub>Y</sub> 720–1,014) and the region comprising residues 526–704 from domain D1–4 (CNF<sub>Y</sub> 1–704). Phases for full-length CNF<sub>Y</sub>C866S were obtained by using both domain D1–4 (CNF<sub>Y</sub>1–704) and D5 (CNF<sub>Y</sub>720–1,014) as search models in molecular replacement. The molecular replacement procedures were carried out using Phaser (McCoy *et al*, 2007) from the Phenix suite (Adams *et al*, 2010). The structural models were built using Coot (Emsley *et al*, 2010) and crystallographic refinement was performed with Phenix.refine (Afonine *et al*, 2012) including the addition of hydrogens in riding positions and TLS-refinement. 5% of random reflections were flagged for the calculation of  $R_{\text{free}}$ . The model of domain D1–4 (CNF<sub>Y</sub> 1–704) was at 3.3 Å resolution and refined to  $R/R_{\text{free}}$  of 24/27% in space group P2<sub>1</sub>. The structure of domain D5 (CNF<sub>Y</sub>720–1,014) was at 1.1 Å resolution and refined to  $R/R_{\text{free}}$  of 17/19% in space group P2<sub>1</sub>. The structure of domain D4–5 (CNF<sub>Y</sub>526–1,014) was at 1.8 Å resolution and refined to  $R/R_{\text{free}}$  of 16/19% in space group P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>. The structural model of the full-length C866S variant of CNF<sub>Y</sub> was at 2.7 Å resolution and refined to  $R/R_{\text{free}}$  of 21/24% in space group I2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>. Data collection and refinement statistics are summarized in Table EV1. Figures of crystal structures were prepared using the PyMOL Molecular Graphics System version 2.0.0 (Schrödinger, LLC).

### Construction of fusion plasmids, N- and C-terminal *cnfY* deletions

To construct the plasmids for CNF<sub>Y</sub> fusion proteins, the *blaM* gene and the 3xFlag tag were amplified using primers listed in Appendix Table S4. pFU189 was used as a backbone from which the *luxCDABE* operon was removed by digestion with *PstI* and *NotI* after which *blaM* or the 3xFlag tag was ligated into the vector, resulting in pTEM and p3xFLAG, respectively.

The PCR fragments of N- and C-terminal *cnfY* deletions containing the *cnfY* promoter region were cloned into the *BamHI* and *PstI* sites of pTEM and p3xFLAG using the Quick-Fusion cloning kit (Biotool) with primers listed in Appendix Table S4. For the construction of pCNF<sub>Y</sub>-GFP, *gfp* was excised from pFU31 and ligated into the *PstI* and *NotI* sites of digested pCNF<sub>Y</sub>-TEM. All clones were transformed into *E. coli* DH10β and confirmed by sequencing. The plasmids were electroporated into *Y. pseudotuberculosis* YP147 (*ΔcnfY*) and selected for on LB agar plates containing the appropriate antibiotics.

### Site-directed mutagenesis of *cnfY*

Amino acid exchanges were generated by site-directed mutagenesis with primers listed in Appendix Table S4. pCNF<sub>Y</sub>-TEM, pCNF<sub>Y</sub>-

3xFLAG were used as templates. Clones were selected on LB containing the appropriate antibiotics. Mutations were verified by DNA sequencing (Microsynth AG).

### Detection of fusion proteins by immunoblotting

For protein expression, strain YP147 harboring the overexpression plasmids encoding full-length CNF<sub>Y</sub> or the deletion variants was grown in BHI at 25°C overnight. Cells were harvested by centrifugation at 5,200 *g* and 4°C for 5 min. Cell pellets were washed with PBS and resuspended with lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.3% Triton X-100, 3 mg/ml lysozyme and protease inhibitor cocktail). After incubation at room temperature for 1 h, protein samples were centrifuged for 10 min and supernatants were sterilized with a 0.2 μm filter. To detect proteins, western blot analysis was performed. The proteins were separated on a 10% SDS–polyacrylamide gel and transferred onto an Immobilon PVDF membrane (Millipore). Membranes were blocked in 5% BSA/TBST at 4°C overnight. Subsequently, the membrane was washed and incubated with primary antibody diluted in 5% BSA/TBST (1:10,000 anti-Flag (Sigma-Aldrich) or anti-β-lactamase (Abcam)) at room temperature for 1 h. After washing, the secondary antibody diluted in 5% skim milk/TBST (1:5,000 anti-mouse IgG-HRP (Cell Signaling Technology)) was added for 30 min at room temperature. After washing the membrane, proteins were visualized using the Western Lightning ECL II Kit (Perkin Elmer) and exposed on X-Ray film (GE Healthcare Amersham Hyperfilm ECL, Fisher Scientific).

### Nitrocefin secretion assay

Bacteria were grown overnight at 25°C in BHI containing the appropriate antibiotics. Subsequently, equal amounts of bacteria were pelleted by centrifugation at 11,500 *g* for 10 min. 95 μl of each supernatant was transferred to a 96-well plate in triplicate. 5 μl nitrocefin (2 mM; Sigma-Aldrich) was added to each well, and the plate was incubated at room temperature for 30 min. β-lactamase activity was determined at 390 nm (yellow) and 486 nm (red) using a VarioSkan plate reader (Thermo Scientific).

### Microbial viability assay

The microbial viability was assessed in equalized bacterial cultures using the BacTiter-Glo™ Microbial Cell Viability Assay kit (Promega) according to the manufacturer's recommendations and luminescence was measured using a VarioSkan plate reader (Thermo Scientific).

### Fluorescent actin staining

HEp-2 cells were seeded onto coverslips at a concentration of 5 × 10<sup>4</sup> cells/well and allowed to attach overnight. The next day, cells were washed and incubated with an equal amount of cleared bacterial cell lysates for 24 h at 37°C, 5% CO<sub>2</sub>. After washing with PBS, cells were fixed in 4% paraformaldehyde for 15 min at room temperature. Subsequently, washed cells were permeabilized with 0.1% Triton X-100 in PBS for 1 min. The actin cytoskeleton was stained with FITC- or TRITC-Phalloidin (0.5 μg/ml in PBS; Sigma-

Aldrich) and mounted on slides using ProLong<sup>®</sup> Gold Antifade mounting medium containing DAPI (Thermo Scientific). Cells were visualized by fluorescence microscopy using an Axiovert II inverted fluorescence microscope (Carl Zeiss) with AxioCam HR and the AxioVision program (Carl Zeiss).

### CNF<sub>γ</sub> translocation assay

In order to study the CNF<sub>γ</sub> translocation into the host cells, a β-lactamase (TEM) reporter assay was performed using the Live-BAZer-FRET B/G Loading Kit with CCF4-AM (Life Technologies). HEp-2 cells were seeded in 8-well μ-slides (Ibidi) at a concentration of  $1.7 \times 10^4$  cells/well and allowed to attach overnight. The next day, cells were washed and incubated for 4 h at 37°C, 5% CO<sub>2</sub> with 20 μg/ml cleared lysates of *Y. pseudotuberculosis* expressing the different CNF<sub>γ</sub>-TEM fusion proteins. Cells were washed with PBS, followed by the addition of fresh media containing 20 mM HEPES. Cells were then stained with loading dye according to the manufacturer's protocol. After staining for 1 h at room temperature, translocation was visualized by fluorescence microscopy using an Axiovert II with AxioCam HR and the AxioVision program (Carl Zeiss).

For the analysis of the translocation dynamics of CNF<sub>γ</sub> 1–1,014 and CNF<sub>γ</sub> 1–526, adherent HEp-2 cells were loaded with CCF4-AM in the dark for 1 h at 37°C and the change of fluorescence was immediately followed after addition of the respective CNF<sub>γ</sub>-TEM fusion construct in *Y. pseudotuberculosis* lysates (20 μg/ml) or the purified recombinant proteins (200 nM), using a CLARIOstar Plus (BMG Labtech) or a Cytation 5 plate reader (Biotek), respectively.

### Fluorescence microscopy to visualize endocytosis

To test whether the CNF<sub>γ</sub> deletion constructs are able to enter the cells through the endocytotic pathway, late Endosomes-RFP (BacMam 2.0, Thermo Scientific) was used to investigate toxin entry to the host cells. HEp-2 cells were seeded  $5 \times 10^4$  cells/ml onto coverslips in 24 well plates and allowed to attach overnight. The next day, CellLight<sup>®</sup> reagent was added to HEp-2 cells at around 20 particles per cells for 16 h and the cells were then incubated with CNF<sub>γ</sub> toxin on ice for 30 min. Subsequently, cells were washed and transferred to 37°C for 30, 90 or 180 min. To investigate colocalization of CNF<sub>γ</sub> with late endosome, cells were then fixed and visualized using a fluorescence microscope (Axiovert II with AxioCam HR, Carl Zeiss) and the AxioVision program (Carl Zeiss).

### Biochemical analysis of RhoA deamidation

Cells were seeded in 10 cm cell culture dishes at the concentration of  $2.2 \times 10^6$  cells/dish and allowed to attach overnight. The next day, cells were washed and incubated for 4 h with 20 μg/ml of cleared lysates from *Y. pseudotuberculosis* expressing different CNF<sub>γ</sub> derivatives at 37°C, 5% CO<sub>2</sub>. Cells were washed with cold PBS and lysed in 150 μl lysis buffer containing 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 2 mM MgCl<sub>2</sub>, 10% NP-40, and 0.5 mM phenyl-methyl-sulfonyl fluoride (PMSF). Cells were then scraped off and centrifuged for 30 min (11,500 g, 4°C). Sodium dodecyl sulfate (SDS) sample buffer was added to the cleared lysates and samples were separated on 12% SDS-gel. After blotting onto a

PVDF membrane, RhoA was detected using mouse anti-RhoA IgG (Millipore) (1:1,000) as a primary antibody and followed by secondary antibody goat anti-mouse IgG-HRP (Cell signaling). Membranes were visualized using the Western Lightning ECL II Kit (Perkin Elmer) and exposed on X-Ray film.

### In vitro RhoA shift assay

*In vitro* RhoA shift assays were performed in order to check for proper folding and catalytic activity of CNF<sub>γ</sub> deletion constructs. Cells were seeded on 150 mm dishes at the concentration of  $5 \times 10^6$  cells/dish and allowed to attach overnight. The next day, cells were washed with PBS and lysed in 300 μl lysis buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl<sub>2</sub>, 1 mM EDTA, 10% NP-40 and 1 mM dithiothreitol (DTT)). Cells were then scraped off and centrifuged at 11,500 g and 4°C for 30 min. 20 μg/ml of cleared lysates from *Y. pseudotuberculosis* expressing different CNF<sub>γ</sub> derivatives were added to the prepared cell extracts and incubated for 4 h. Alternatively, 1 μM purified CNF<sub>γ</sub> or CNF<sub>γ</sub> 526–1,014 protein was incubated in the cell extracts for 10–60 min at 37°C. The reactions were stopped by adding SDS-sample buffer and heated at 95°C for 10 min. Samples were then subjected to 12% SDS-PAGE. After blotting onto a PVDF membrane, blots were developed as mentioned above.

### Quantification of RhoA deamidation by mass spectrometry

Recombinant RhoA (20 μM) was incubated at 37°C with full-length CNF<sub>γ</sub> or CNF<sub>γ</sub> 526–1,014 in 100 μl assay-buffer (20 mM HEPES/NaOH, 300 mM NaCl, 2 mM MgCl<sub>2</sub>, 2 mM TCEP, 100 μM GDP). Samples, after set-up for 30 min, 3 or 16 h, were immediately mixed with twofold SDS-PAGE loading buffer, denatured for 5 min at 95°C and subjected to SDS-PAGE by applying 2 μg of RhoA per lane. After staining with Coomassie Blue, bands corresponding to RhoA were cut out, destained with 30% acetonitrile in 50 mM TEAB, and then dehydrated with 100% acetonitrile. After reduction with 20 mM TCEP in 50 mM TEAB (1 h, 56°C), alkylation was performed by 20 mM MMTS in 50 mM TEAB (1 h, RT), followed by in-gel digestion over night with 50 ng trypsin (Promega) in 50 mM TEAB. Peptides were extracted by using 10 gel volumes of 0.5% formic acid in 30% acetonitrile, vacuum dried, and resuspended in 0.1% formic acid before applying to Evtips as recommended by the manufacturer (Evosep). Peptide sequencing of RhoA was carried out by tandem mass spectrometry on an Evosep One HPLC system linked with a timsTOF Pro mass spectrometer (Bruker). Separation of modified peptide ions was supported by ion mobility, and RhoA deamidation in the peptide QVELALWDTAGQE-DYDR was identified by using PEAKS 10+ software. Deamidated and corresponding non-deamidated RhoA peptide variants were manually validated at the level of their distinct HPLC-retention times and corresponding representative fragmentation spectra (MS2; Data Analysis, Bruker). RhoA modification was then quantified by selected ion chromatograms (MS1; Data Analysis, Bruker). CNF<sub>γ</sub>-dependent deamidation was determined in comparison to non-treated RhoA samples (negative control) and based on the area under peaks for double-charged non-deamidated peptides ( $m/z$  1,004.9645 ± 0.005) and deamidated peptides (retention time + 0.3 min,  $m/z$  1,005.4590 ± 0.005).

## Data availability

Coordinates and structure factor amplitudes have been deposited in the Protein Data Bank with accession codes 6YHK (CNF<sub>Y</sub> 1–1,014 C866S; <https://www.rcsb.org/structure/6YHK>), 6YHL (CNF<sub>Y</sub> 1–704; <https://www.rcsb.org/structure/6YHL>), 6YHM (CNF<sub>Y</sub> 720–1,014, <https://www.rcsb.org/structure/6YHM>), and 6YHN (CNF<sub>Y</sub> 526–1,014; <https://www.rcsb.org/structure/6YHN>).

**Expanded View** for this article is available online.

## Acknowledgements

We thank the beamline staff at the Helmholtz Centre Berlin (Germany) and the Paul Scherrer Institute (Villigen, Switzerland) for providing access to beamlines BL14.1 and BL14.2 at the BESSYII electron storage ring and to beamline X06DA at the SLS synchrotron. Experiments at the SLS have received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 730872, project CALIPSOplus. Andrea Berger and Ute Widow are acknowledged for excellent technical assistance. We thank Janina Schweer for the construction of initial plasmids and strains. Manfred Nimtz and Josef Wissing helped with mass spectrometry experiments. PD and PC received funding from the SFB1009 (Project no. 194468054) of the German Research Foundation (DFG). TH and PC were supported by the HZI Graduate School for Infection Research.

## Author contributions

PD and WBI conceived the project. PL, EM-G, and TH produced recombinant proteins and performed crystallization and structure determination. CR, PC, SM, and TEBS conducted work with *Y. pseudotuberculosis* and analyzed microscopy experiments with eukaryotic cells. Similar microscopy experiments with recombinant proteins were performed by AS, MK, and SD. WBI and LJ performed and analyzed mass-spectrometric experiments. PD, PL, SM, and WBI wrote the manuscript.

## Conflict of interest

The authors declare that they have no conflict of interest.

## References

- Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung L-W, Kapral GJ, Grosse-Kunstleve RW *et al* (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66: 213–221
- Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD (2012) Towards automated crystallographic structure refinement with phenix.refine. *Acta Crystallogr D Biol Crystallogr* 68: 352–367
- Aleksiev T, Potestio R, Pontiggia F, Cozzini S, Micheletti C (2009) PiSQRD: a web server for decomposing proteins into quasi-rigid dynamical domains. *Bioinformatics* 25: 2743–2744
- Bergmann S, Jehle D, Schwan C, Orth JHC, Aktories K (2013) Pasteurella multocida toxin as a transporter of non-cell-permeating proteins. *Infect Immun* 81: 2459–2467
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. *Nucleic Acids Res* 28: 235–242
- Blumenthal B, Hoffmann C, Aktories K, Backert S, Schmidt G (2007) The cytotoxic necrotizing factors from *Yersinia pseudotuberculosis* and from *Escherichia coli* bind to different cellular receptors but take the same route to the cytosol. *Infect Immun* 75: 3344–3353
- Boquet P (2001) The cytotoxic necrotizing factor 1 (CNF1) from *Escherichia coli*. *Toxicon* 39: 1673–1680
- Buetow L, Flatau G, Chiu K, Boquet P, Ghosh P (2001) Structure of the Rho-activating domain of *Escherichia coli* cytotoxic necrotizing factor 1. *Nat Struct Biol* 8: 584–588
- Buetow L, Flatau G, Chiu K, Boquet P, Ghosh P (2002) Strategies for the structural determination of the catalytic domain of *Escherichia coli* cytotoxic necrotizing factor 1. *Acta Crystallogr D Biol Crystallogr* 58: 366–369
- Cavaillon J-M (2018) Exotoxins and endotoxins: inducers of inflammatory cytokines. *Toxicon* 149: 45–53
- Chung JW, Hong SJ, Kim KJ, Goti D, Stins MF, Shin S, Dawson VL, Dawson TM, Kim KS (2003) 37-kDa laminin receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake. *J Biol Chem* 278: 16857–16862
- Clemons NC, Bannai Y, Haywood EE, Xu Y, Buschbach JD, Ho M, Wilson BA (2018) Cytosolic delivery of multidomain cargos by the N terminus of *Pasteurella multocida* toxin. *Infect Immun* 86: e00248-18
- Cohen MS, Chang P (2018) Insights into the biogenesis, function, and regulation of ADP-ribosylation. *Nat Chem Biol* 14: 236–243
- Cruz-Migoni A, Hautbergue GM, Artymiuk PJ, Baker PJ, Bokori-Brown M, Chang C-T, Dickman MJ, Essex-Lopresti A, Harding SV, Mahadi NM *et al* (2011) A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. *Science* 334: 821–824
- Diabate M, Munro P, Garcia E, Jacquelin A, Michel G, Obba S, Goncalves D, Luci C, Marchetti S, Demon D *et al* (2015) *Escherichia coli* alpha-hemolysin counteracts the anti-virulence innate immune response triggered by the Rho GTPase activating toxin CNF1 during bacteremia. *PLoS Pathog* 11: e1004732
- Diana G, Valentini G, Travaglione S, Falzano L, Pieri M, Zona C, Meschini S, Fabbri A, Fiorentini C (2007) Enhancement of learning and memory after activation of cerebral Rho GTPases. *Proc Natl Acad Sci USA* 104: 636–641
- Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* 66: 486–501
- Evans P (2006) Scaling and assessment of data quality. *Acta Crystallogr D Biol Crystallogr* 62: 72–82
- Evans PR, Murshudov GN (2013) How good are my data and what is the resolution? *Acta Crystallogr D Biol Crystallogr* 69: 1204–1214
- Fabbri A, Gauthier M, Boquet P (1999) The 5' region of cnf1 harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell-binding domain of the toxin. *Mol Microbiol* 33: 108–118
- Fabbri A, Travaglione S, Ballan G, Loizzo S, Fiorentini C (2013) The cytotoxic necrotizing factor 1 from *E. coli*: a janus toxin playing with cancer regulators. *Toxins (Basel)* 5: 1462–1474
- Fabbri A, Travaglione S, Maroccia Z, Guidotti M, Pierri CL, Primiano G, Servidei S, Loizzo S, Fiorentini C (2018) The bacterial protein CNF1 as a potential therapeutic strategy against mitochondrial diseases: a pilot study. *Int J Mol Sci* 19: 1825
- Fabbri A, Travaglione S, Rosadi F, Ballan G, Maroccia Z, Giambenedetti M, Guidotti M, Ødum N, Krejsgaard T, Fiorentini C (2019) The *Escherichia coli* protein toxin cytotoxic necrotizing factor 1 induces epithelial mesenchymal transition. *Cell Microbiol* 22: e13138
- Falzano L, Fiorentini C, Donelli G, Michel E, Kocks C, Cossart P, Cabanie L, Oswald E, Boquet P (1993) Induction of phagocytic behaviour in human

- epithelial cells by *Escherichia coli* cytotoxic necrotizing factor type 1. *Mol Microbiol* 9: 1247–1254
- Fieldhouse RJ, Merrill AR (2008) Needle in the haystack: structure-based toxin discovery. *Trends Biochem Sci* 33: 546–556
- Flatau G, Lemichez E, Gauthier M, Chardin P, Paris S, Fiorentini C, Boquet P (1997) Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. *Nature* 387: 729–733
- Fournout S, Dozois C, Odin M, Desautels C, Pérès S, Héroult F, Daigle F, Segafredo C, Laffitte J, Oswald E et al (2000) Lack of a role of cytotoxic necrotizing factor 1 toxin from *Escherichia coli* in bacterial pathogenicity and host cytokine response in infected germfree piglets. *Infect Immun* 68: 839–847
- Galloway TS, van Heyningen S (1987) Binding of NAD<sup>+</sup> by cholera toxin. *Biochem J* 244: 225–230
- Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A (2003) Expasy: the proteomics server for in-depth protein knowledge and analysis. *Nucleic Acids Res* 31: 3784–3788
- Gouet P, Robert X, Courcelle E (2003) ESPript/ENDscript: extracting and rendering sequence and 3D information from atomic structures of proteins. *Nucleic Acids Res* 31: 3320–3323
- Haywood EE, Ho M, Wilson BA (2018) Modular domain swapping among the bacterial cytotoxic necrotizing factor (CNF) family for efficient cargo delivery into mammalian cells. *J Biol Chem* 293: 3860–3870
- Heine W, Beckstette M, Heroven AK, Thiemann S, Heise U, Nuss AM, Pisano F, Strowig T, Dersch P (2018) Loss of CNFY toxin-induced inflammation drives *Yersinia pseudotuberculosis* into persistency. *PLoS Pathog* 14: e1006858
- Ho M, Mettouchi A, Wilson BA, Lemichez E (2018) CNF1-like deamidase domains: common Lego bricks among cancer-promoting immunomodulatory bacterial virulence factors. *Pathog Dis* 76: fty045
- Hodge R, Ridley A (2016) Regulating Rho GTPases and their regulators. *Nat Rev Mol Cell Biol* 17: 496–510
- Hoffmann C, Pop M, Leemhuis J, Schirmer J, Aktories K, Schmidt G (2004) The *Yersinia pseudotuberculosis* cytotoxic necrotizing factor (CNFY) selectively activates RhoA. *J Biol Chem* 279: 16026–16032
- Hoffmann C, Aktories K, Schmidt G (2007) Change in substrate specificity of cytotoxic necrotizing factor unmasks proteasome-independent down-regulation of constitutively active RhoA. *J Biol Chem* 282: 10826–10832
- Holm L, Rosenström P (2010) Dali server: conservation mapping in 3D. *Nucleic Acids Res* 38(Suppl): W545–W549
- Jørgensen R, Wang Y, Visschedyk D, Merrill AR (2008) The nature and character of the transition state for the ADP-ribosyltransferase reaction. *EMBO Rep* 9: 802–809
- Kabsch W (2010) XDS. *Acta Crystallogr D Biol Crystallogr* 66: 125–132
- Khan NA, Wang Y, Kim KJ, Chung JW, Wass CA, Kim KS (2002) Cytotoxic necrotizing factor-1 contributes to *Escherichia coli* K1 invasion of the central nervous system. *J Biol Chem* 277: 15607–15612
- Kim KJ, Chung JW, Kim KS (2005) 67-kDa laminin receptor promotes internalization of cytotoxic necrotizing factor 1-expressing *Escherichia coli* K1 into human brain microvascular endothelial cells. *J Biol Chem* 280: 1360–1368
- Knust Z, Blumenthal B, Aktories K, Schmidt G (2009) Cleavage of *Escherichia coli* cytotoxic necrotizing factor 1 is required for full biologic activity. *Infect Immun* 77: 1835–1841
- Knust Z, Schmidt G (2010) Cytotoxic necrotizing factors (CNFs)-A growing toxin family. *Toxins (Basel)* 2: 116–127
- Koornhof HJ, Megso RA, Nicol M (1999) Yersiniosis. II: the pathogenesis of *Yersinia* infections. *Eur J Clin Microbiol Infect Dis* 18: 87–112
- Kowarschik S, Schöllkopf J, Müller T, Tian S, Knerr J, Bakker H, Rein S, Dong M, Weber S, Grosse R et al (2020) Glycosaminoglycans are specific endosomal receptors for *Yersinia pseudotuberculosis* Cytotoxic Necrotizing Factor. *bioRxiv* <https://doi.org/10.1101/2020.05.18.101790> [PREPRINT]
- Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. *J Mol Biol* 372: 774–797
- Labreuche Y, Chenivresse S, Jeudy A, Le Panse S, Boulo V, Ansquer D, Pagès S, Givaudan A, Czjzek M, Le Roux F (2017) Nigritoxin is a bacterial toxin for crustaceans and insects. *Nat Commun* 8: 1248
- Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* 23: 2947–2948
- Marocchia Z, Loizzo S, Travaglione S, Frank C, Fabbri A, Fiorentini C (2018) New therapeutics from Nature: The odd case of the bacterial cytotoxic necrotizing factor 1. *Biomed Pharmacother* 101: 929–937
- McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. *J Appl Crystallogr* 40: 658–674
- McNichol BA, Rasmussen SB, Carvalho HM, Meysick KC, O'Brien AD (2007) Two domains of cytotoxic necrotizing factor type 1 bind the cellular receptor, laminin receptor precursor protein. *Infect Immun* 75: 5095–5104
- Monnappa AK, Bari W, Seo JK, Mitchell RJ (2018) The cytotoxic necrotizing factor of *Yersinia pseudotuberculosis* (CNFY) is carried on extracellular membrane vesicles to host cells. *Sci Rep* 8: 14186
- Morgan RN, Saleh SE, Farrag HA, Aboulwafa MM (2019) Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in *Escherichia coli*: experimental and bioinformatics analyses. *Gut Pathog* 11: 22
- Mueller U, Förster R, Hellmig M, Huschmann FU, Kastner A, Malecki P, Pühringer S, Röwer M, Sparta K, Steffien M et al (2015) The macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: Current status and perspectives. *Eur Phys J Plus* 130: 141
- Murphy JR (2011) Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. *Toxins* 3: 294–308
- Orrell KE, Zhang Z, Sugiman-Marangos SN, Melnyk RA (2017) Clostridium difficile toxins A and B: receptors, pores, and translocation into cells. *Crit Rev Biochem Mol Biol* 52: 461–473
- Pei S, Doye A, Boquet P (2001) Mutation of specific acidic residues of the CNF1 T domain into lysine alters cell membrane translocation of the toxin. *Mol Microbiol* 41: 1237–1247
- Pei J, Kim B-H, Grishin NV (2008) PROMALS3D: a tool for multiple protein sequence and structure alignments. *Nucleic Acids Res* 36: 2295–2300
- Pitard I, Malliavin TE (2019) Structural biology and molecular modeling to analyze the entry of bacterial toxins and virulence factors into host cells. *Toxins* 11: 369
- Piteau M, Papatheodorou P, Schwan C, Schlosser A, Aktories K, Schmidt G (2014) Lu/BCAM adhesion glycoprotein is a receptor for *Escherichia coli* Cytotoxic Necrotizing Factor 1 (CNF1). *PLoS Pathog* 10: e1003884
- Popoff MR (2005) Bacterial exotoxins. *Contrib Microbiol* 12: 28–54
- Reppin F, Cochet S, El Nemer W, Fritz G, Schmidt G (2017) High affinity binding of *Escherichia coli* cytotoxic necrotizing factor 1 (CNF1) to Lu/BCAM adhesion glycoprotein. *Toxins* 10: 3
- Rippere-Lampe KE, Lang M, Ceri H, Olson M, Lockman HA, O'Brien AD (2001) Cytotoxic necrotizing factor type 1-positive *Escherichia coli* causes increased inflammation and tissue damage to the prostate in a rat prostatitis model. *Infect Immun* 69: 6515–6519
- Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res* 42: W320–324

- Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K (1997) Gln 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. *Nature* 387: 725–729
- Schweer J, Kulkarni D, Kochut A, Pezoldt J, Pisano F, Pils MC, Genth H, Huehn J, Dersch P (2013) The cytotoxic necrotizing factor of *Yersinia pseudotuberculosis* (CNFY) enhances inflammation and Yop delivery during infection by activation of Rho GTPases. *PLoS Pathog* 9: e1003746
- Smego RA, Frea J, Koornhof HJ (1999) Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague *Yersinia* infections. *Eur J Clin Microbiol Infect Dis* 18: 1–15
- Studier FW (2005) Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41: 207–234
- Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH (2015) UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. *Bioinformatics* 31: 926–932
- Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, Hung LW, Read RJ, Adams PD (2008) Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr D Biol Crystallogr* 64: 61–69
- Terwilliger TC, Adams PD, Read RJ, McCoy AJ, Moriarty NW, Grosse-Kunstleve RW, Afonine PV, Zwart PH, Hung LW (2009) Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. *Acta Crystallogr D Biol Crystallogr* 65: 582–601
- Tsurumura T, Tsumori Y, Qiu H, Oda M, Sakurai J, Nagahama M, Tsuge H (2013) Arginine ADP-ribosylation mechanism based on structural snapshots of iota-toxin and actin complex. *Proc Natl Acad Sci USA* 110: 4267–4272
- Vannini E, Olimpico F, Middei S, Ammassari-Teule M, de Graaf EL, McDonnell L, Schmidt G, Fabbri A, Fiorentini C, Baroncelli L et al (2016) Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function. *Neuro-oncology* 18: 1634–1643
- Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne G (2011) Data processing and analysis with the autoPROC toolbox. *Acta Crystallogr D Biol Crystallogr* 67: 293–302
- Walker KE, Weiss AA (1994) Characterization of the dermonecrotic toxin in members of the genus *Bordetella*. *Infect Immun* 62: 3817–3828
- Wolters M, Boyle EC, Lardong K, Trülsch K, Steffen A, Rottner K, Ruckdeschel K, Aepfelbacher M (2013) Cytotoxic necrotizing factor-Y boosts *Yersinia* effector translocation by activating Rac protein. *J Biol Chem* 288: 23543–23553
- Zhang Z, Aung KM, Uhlin BE, Wai SN (2018) Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from *Escherichia coli*. *Sci Rep* 8: 17780



**License:** This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDeriv 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.